Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
Carcinoma, Non-Small-Cell Lung|Lung Cancer
DRUG: Nexavar (Sorafenib, BAY43-9006)|DRUG: Nexavar (Sorafenib, BAY43-9006)|DRUG: Bevacizumab|DRUG: Bevacizumab|DRUG: Bevacizumab|DRUG: Bevacizumab|DRUG: Paclitaxel|DRUG: Carboplatin
The primary objective of this study is to define the safety profile and maximum tolerated dose (MTD) of BAY43-9006 (sorafenib) administered in combination with, carboplatin, paclitaxel and bevacizumab, 2 years
The secondary objectives include evaluation of pharmacokinetics, biomarkers, pharmacodynamics and tumor response of patients treated with BAY43-9006 (sorafenib) in combination with bevacizumab, paclitaxel and carboplatin, 2 years
To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.